Axiogenesis claims that its Cor.At murine ESC-derived cardiomyocytes represent the first physiologically relevant disease model of cardiomyopathy. Lonza negotiated exclusive, worldwide rights to ...

Sigma-Aldrich® Corporation announced that Sigma Life Science, its innovative biological products and services research business, has signed an agreement with Axiogenesis to market mouse induced ...

Axiogenesis AG and Metrion Biosciences Ltd have signed a collaboration agreement to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately ...

Nanion and Axiogenesis present parallel patch clamp recordings of action potentials from Cor.At cardiomyocytes Stem cell derived cardiomyocytes were analyzed using Nanion’s automated patch clamp ...

A major constraint in the development of effective drug treatments for chronic heart failure has been the lack of suitable cell-based assays and disease models with physiological relevance. Recently, ...